Research & Innovation

Millions of Americans—including veterans, first responders, seniors, and trauma survivors—face barriers accessing treatments that may improve their quality of life because insurance coverage has not kept pace with scientific research. AACPN's Alternative Care Access Campaign advocates for Medicare, Medicaid, VA, and private insurance policies that incorporate evidence-based alternative and integrative healthcare treatments shown to be safe, effective, and beneficial to patien

AACPN is calling for expanded scientific research into psychedelic-assisted therapies as potential trauma treatment options for survivors of sexual violence. The organization says survivors deserve compassionate, evidence-based care and continued research into emerging mental health therapies including MDMA, psilocybin, and ketamine-assisted treatment.

The American Alternative Care Policy Network (AACPN) this week launched its Psychedelic Research Initiative to support continued scientific research into emerging therapies that may help address some of America's most difficult mental health challenges. At the center of this effort are veterans. For many veterans, the invisible wounds of service can persist long after they return home. Post-traumatic stress, depression, anxiety, traumatic brain injury, substance-use disorders

AACPN applauds Connecticut’s enactment of Public Act 26-108, expanding the state’s psychedelic-assisted therapy pilot program and supporting continued clinical research involving MDMA and psilocybin therapies for veterans, first responders, trauma survivors, and individuals living with treatment-resistant mental health conditions.

The U.S. Department of Veterans Affairs has launched a new MDMA-assisted therapy clinical trial focused on veterans with PTSD and trauma-related conditions. The initiative reflects growing interest in evidence-based psychedelic-assisted therapies and broader efforts to expand innovative mental health treatment options for veterans and other trauma survivors.